NCT00082719View on ClinicalTrials.gov

Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

December 31, 2003

Primary Completion Date

January 31, 2015

Study Completion Date

January 31, 2015

Conditions
Bladder CancerUrethral Cancer
Interventions
BIOLOGICAL

Recombinant Interferon Alfa

"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.~Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."

Trial Locations (1)

77030-4009

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00082719 - Short-Term Low-Dose Interferon Alfa in Treating Patients With Cancer of the Urothelium | Biotech Hunter | Biotech Hunter